SLE - IFN Based Therapies Rationale and Data
WebcastFaculty
OVERVIEW
SLE - IFN Based Therapies Rationale and Data is organized by Cleveland Clinic Center for Continuing Education and would be held during May 25, 2017 - May 25, 2019.
The target audience for this medical event for rheumatologists, allergists / immunologists, dermatologists, internal medicine physicians, and associated allied health practitioners, including nurse practitioners, nurses, and physician assistants interested in or using biologic therapeutics for autoimmune and inflammatory disorders. This CME Conference has been approved with a maximum of 0.50 AMA PRA Category 1 Credits.
Description :
Biologic Therapies VII: Precision Medicine in the Biologic Era online series brings together world leaders in immune-based therapies and addresses cutting-edge translational immunology and the latest data on biologic therapeutics.
This webcast will review the current lupus therapies and approaches to eliminate B cells in SLE. This presentation will also cover specific therapeutic agents and regimens and determine if they are sufficiently optimized to the pathogenesis of lupus.
Learning Objectives :
• Define the approved therapeutic options for lupus patients, and ACR guideline for lupus nephritis. • Describe a range of targeted therapies now in clinical development.
Additional details will be posted as soon as they are available.
The target audience for this medical event for rheumatologists, allergists / immunologists, dermatologists, internal medicine physicians, and associated allied health practitioners, including nurse practitioners, nurses, and physician assistants interested in or using biologic therapeutics for autoimmune and inflammatory disorders. This CME Conference has been approved with a maximum of 0.50 AMA PRA Category 1 Credits.
Description :
Biologic Therapies VII: Precision Medicine in the Biologic Era online series brings together world leaders in immune-based therapies and addresses cutting-edge translational immunology and the latest data on biologic therapeutics.
This webcast will review the current lupus therapies and approaches to eliminate B cells in SLE. This presentation will also cover specific therapeutic agents and regimens and determine if they are sufficiently optimized to the pathogenesis of lupus.
Learning Objectives :
• Define the approved therapeutic options for lupus patients, and ACR guideline for lupus nephritis. • Describe a range of targeted therapies now in clinical development.
Additional details will be posted as soon as they are available.
SPECIALITIES
Cell and Developmental Biology
Quick Links